WINT Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Windtree Therapeutics's net margin of --. Windtree Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 95.12%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 258.97%. Given that Armata Pharmaceuticals has higher upside potential than Windtree Therapeutics, analysts believe Armata Pharmaceuticals is more attractive than Windtree Therapeutics.

Windtree Therapeutics has a beta of 0.679, which suggesting that the stock is 32.118% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.295%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Windtree Therapeutics's net income of -$2.7M is higher than Armata Pharmaceuticals's net income of -$5.5M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.03x versus 706.46x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Windtree Therapeutics's net margin of --. Windtree Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 95.12%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than Windtree Therapeutics, analysts believe Perspective Therapeutics is more attractive than Windtree Therapeutics.

Windtree Therapeutics has a beta of 0.679, which suggesting that the stock is 32.118% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Windtree Therapeutics's net income of -$2.7M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.03x versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Windtree Therapeutics's net margin of 12.11%. Windtree Therapeutics's return on equity of -- beat Electromed's return on equity of 15.91%.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 95.12%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Windtree Therapeutics has higher upside potential than Electromed, analysts believe Windtree Therapeutics is more attractive than Electromed.

Windtree Therapeutics has a beta of 0.679, which suggesting that the stock is 32.118% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Windtree Therapeutics's net income of -$2.7M is lower than Electromed's net income of $2M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.03x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Windtree Therapeutics's net margin of 18.02%. Windtree Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Windtree Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 95.12%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 547.32%. Given that Protalix BioTherapeutics has higher upside potential than Windtree Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Windtree Therapeutics.

Windtree Therapeutics has a beta of 0.679, which suggesting that the stock is 32.118% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

Windtree Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Windtree Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Windtree Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Windtree Therapeutics's net income of -$2.7M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Windtree Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Windtree Therapeutics is 0.03x versus 3.85x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.